Rocket Pharmaceuticals(RCKT) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress • Engagement with the FDA is ongoing regarding RP-A601 for PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). o Rocket continues to collaborate with the FDA to align upon potential pivotal Phase 2 trial design to evaluate the efficacy and safety of RP-A601 for PKP2-ACM. • Phase 1 trial start-up activities are ongoing for RP-A701 in BAG3-associated dilated cardiomyopathy (BAG3-DCM). o The first-in-huma ...